论文部分内容阅读
目的应用水飞蓟宾-磷脂酰胆碱复合物联合还原型谷胱甘肽治疗脂肪肝。方法选择2014年1月—2016年6月收治的脂肪肝飞行员55例。随机分为对照组27例,治疗组28例。对照组27例采用常规治疗,包括去除病因、合理膳食运动,对血脂有异常者给予降脂治疗。治疗组28例在常规治疗基础上加用还原型谷胱甘肽1.8 g加入5%葡萄糖液250 ml中静脉滴注,1次/d。服水飞蓟宾-磷脂酰胆碱复合物140 mg,3次/d,疗程15~30 d。观察指标:治疗前及治疗后2、4周分别检查肝功能指标ALT、AST、GGT及血脂,同时观察临床症状和体征变化,复查腹部B超。结果治疗组与对照组治疗后恢复正常率AST 83%、56%;ALT 88%、61%;GGT 52%、19%;2组比较差异有统计学意义(P<0.05)。2组综合疗效比较,治疗组有效率89%,对照组有效率54%,2组比较差异有统计学意义(P<0.05)。治疗期间2组患者均未发生明显不良反应。结论还原型谷胱甘肽联合水飞蓟宾-磷脂酰胆碱复合物治疗脂肪肝有效、安全,值得临床选用。
Objective To apply silybin - phosphatidylcholine complex combined with reduced glutathione for the treatment of fatty liver. Methods From January 2014 to June 2016, 55 patients with fatty liver pilots were enrolled. Randomly divided into control group of 27 cases, 28 cases of treatment group. Control group, 27 cases of conventional treatment, including the removal of the cause, reasonable diet, lipid abnormalities were given lipid-lowering treatment. In the treatment group, 28 cases were treated with intravenous drip of 250 ml of 5% dextrose solution and 1.8 g of reduced glutathione once daily on the basis of routine treatment. Take silybin - phosphatidylcholine compound 140 mg, 3 times / d, treatment of 15 ~ 30 d. Observed indicators: before treatment and after 2, 4 weeks of treatment were examined liver function indicators ALT, AST, GGT and blood lipids, while observing the clinical signs and symptoms, review of the abdominal B-ultrasonography. Results After treatment, the normalized rates of recovery in treatment group and control group were 83%, 56%; ALT 88%, 61%; GGT 52%, 19% respectively. There was significant difference between the two groups (P <0.05). In the two groups, the effective rate was 89% in the treatment group and 54% in the control group, the difference between the two groups was statistically significant (P <0.05). No significant adverse reactions occurred in both groups during treatment. Conclusions Reduced glutathione combined with silybin-phosphatidylcholine complex is effective and safe in the treatment of fatty liver and is worthy of clinical application.